159 related articles for article (PubMed ID: 15618966)
1. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia.
von Bubnoff N; Sandherr M; Schlimok G; Andreesen R; Peschel C; Duyster J
Leukemia; 2005 Feb; 19(2):286-7. PubMed ID: 15618966
[No Abstract] [Full Text] [Related]
2. Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation.
Pardanani A; Lasho T; Barraco D; Patnaik M; Elala Y; Tefferi A
Am J Hematol; 2016 Mar; 91(3):E10-1. PubMed ID: 26663400
[No Abstract] [Full Text] [Related]
3. [The efficacy of imatinib mesylate for patients with myeloproliferative neoplasm (MPN) with eosinophilia].
Zhang Y; Qin TJ; Zhou CL; Liu L; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2009 Jun; 30(6):381-4. PubMed ID: 19951530
[TBL] [Abstract][Full Text] [Related]
4. Myeloid neoplasms with eosinophilia and FIP1L1-PDGFRA fusion gene: another point of view.
Helbig G; Kyrcz-Krzemien S
Leuk Lymphoma; 2013 Apr; 54(4):897-8. PubMed ID: 23025324
[No Abstract] [Full Text] [Related]
5. Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis.
Uchida T; Kitaura J; Nakahara F; Togami K; Inoue D; Maehara A; Nishimura K; Kawabata KC; Doki N; Kakihana K; Yoshioka K; Izawa K; Oki T; Sada A; Harada Y; Ohashi K; Katayama Y; Matsui T; Harada H; Kitamura T
Exp Hematol; 2014 May; 42(5):369-379.e3. PubMed ID: 24486648
[TBL] [Abstract][Full Text] [Related]
6. Myeloid neoplasm with rearrangement of PDGFRA, but with no significant eosinophilia: should we broaden the World Health Organization definition of the entity?
Rudzki Z; Giles L; Cross NC; Lumley M
Br J Haematol; 2012 Mar; 156(5):558. PubMed ID: 22224867
[No Abstract] [Full Text] [Related]
7. A case of myeloid neoplasm with FIP1L1-PDGFRA rearrangement without marked peripheral blood eosinophilia.
Wang J; Zhang Q; Zeng H; Chen B; Ouyang J
Pharmacogenomics; 2016; 17(2):99-102. PubMed ID: 26666578
[TBL] [Abstract][Full Text] [Related]
8. Transient macular erythema with eosinophilia in a patient carrying the FIP1L1-PDGFRA fusion gene.
Yahara H; Satoh T; Hashimoto T; Yokozeki H
Br J Dermatol; 2007 Dec; 157(6):1284-7. PubMed ID: 17916194
[No Abstract] [Full Text] [Related]
9. Molecular analysis of PDGFRalpha/beta genes in core binding factor leukemia with eosinophilia.
Monma F; Nishii K; Lorenzo F; Usui E; Ueda Y; Watanabe Y; Kawakami K; Oka K; Mitani H; Sekine T; Tamaki S; Mizutani M; Yagasaki F; Doki N; Miyawaki S; Katayama N; Shiku H
Eur J Haematol; 2006 Jan; 76(1):18-22. PubMed ID: 16343267
[TBL] [Abstract][Full Text] [Related]
10. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
Metzgeroth G; Walz C; Score J; Siebert R; Schnittger S; Haferlach C; Popp H; Haferlach T; Erben P; Mix J; Müller MC; Beneke H; Müller L; Del Valle F; Aulitzky WE; Wittkowsky G; Schmitz N; Schulte C; Müller-Hermelink K; Hodges E; Whittaker SJ; Diecker F; Döhner H; Schuld P; Hehlmann R; Hochhaus A; Cross NC; Reiter A
Leukemia; 2007 Jun; 21(6):1183-8. PubMed ID: 17377585
[TBL] [Abstract][Full Text] [Related]
11. Atypical Phenotype and Treatment Response Pattern in a Patient with FIP1L1-PDGFRα Mutation.
Bikhchandani M; Johnson R; Tuan B; Tefferi A
Acta Haematol; 2018; 140(2):67-70. PubMed ID: 30184522
[TBL] [Abstract][Full Text] [Related]
12. A challenging diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement.
Coltro G; Santi R
Blood; 2023 May; 141(20):2541. PubMed ID: 37200055
[No Abstract] [Full Text] [Related]
13. Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T6741 mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy.
Ohnishi H; Kandabashi K; Maeda Y; Kawamura M; Watanabe T
Br J Haematol; 2006 Sep; 134(5):547-9. PubMed ID: 16856885
[No Abstract] [Full Text] [Related]
14. Case of polycythemia vera concurrent with FIP1L1-PDGFRA-positive myeloproliferative neoplasm with eosinophilia.
Alrwas A; Quesada JR; Marcos LA; Mehta SS; Shattuck BL; Nguyen ND; Juneja HS
Cancer Genet; 2012 Oct; 205(10):519-22. PubMed ID: 22944561
[TBL] [Abstract][Full Text] [Related]
15. Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid.
Miyazawa K; Kakazu N; Ohyashiki K
Int J Hematol; 2007 Jan; 85(1):5-10. PubMed ID: 17261495
[TBL] [Abstract][Full Text] [Related]
16. Progressive multifocal leukoencephalopathy responsive to withdrawal of imatinib in a patient with FIP1L1-PDGFRA positive myeloid neoplasm.
Blum S; Dunet V; Comoli P; Tirefort Y; Chalandon Y; Opota O; Comte D; Spertini O; Livio F; Brouland JP; Du Pasquier R
Leuk Lymphoma; 2020 Sep; 61(9):2226-2229. PubMed ID: 32364409
[No Abstract] [Full Text] [Related]
17. Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase.
Metzgeroth G; Schwaab J; Gosenca D; Fabarius A; Haferlach C; Hochhaus A; Cross NC; Hofmann WK; Reiter A
Leukemia; 2013 Nov; 27(11):2254-6. PubMed ID: 23615556
[No Abstract] [Full Text] [Related]
18. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.
Rathe M; Kristensen TK; Møller MB; Carlsen NL
Pediatr Blood Cancer; 2010 Oct; 55(4):730-2. PubMed ID: 20589620
[TBL] [Abstract][Full Text] [Related]
19. [Myeloproliferative hypereosinophilic syndrome revealed by bipolar mucosal ulcerations].
Isvy-Joubert A; Hickman G; Flageul B; Battistella M; Bagot M; Galicier L; Petit A
Ann Dermatol Venereol; 2012 Oct; 139(10):636-40. PubMed ID: 23122377
[TBL] [Abstract][Full Text] [Related]
20. Myeloid Neoplasm With Eosinophilia and FIP1L1-PDGFRA Rearrangement Treated With Imatinib Mesylate: A Pediatric Case With Long-term Follow-up.
Srinivasan A; Scordino T; Baker A
J Pediatr Hematol Oncol; 2019 May; 41(4):334-335. PubMed ID: 30807397
[No Abstract] [Full Text] [Related]
[Next] [New Search]